5% Off
Ferinject500 mg
Unimed Unihealth MFG. Ltd.
৳3258.50
Add to cart
Ferintus500 mg
IV Injection
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Ferintus 500 mg
Ferintus 500 mg is indicated for the treatment of iron deficiency anemia in adult patients-
Who have intolerance to oral iron or have had unsatisfactory response to oral iron
Who have non-dialysis dependent chronic kidney disease.
Theropeutic Class
Parenteral Iron Preparations
Pharmacology
Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release.
Metabolism
Transferrin saturates and, Iron into the liver, spleen and Bone marrow.
Dosage & Administration of Ferintus 500 mg
For patients weighing 50 kg or more
Dosage:Give Ferintus 500 mg in two doses separated by at least 7 days
Notes:Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course
For patients weighing less than 50 kg
Dosage:Give Ferintus 500 mg in two doses separated by at least 7 days
Notes:Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course. The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency anemia reoccurs. Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes. When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded. Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site
| Condition | Dosage | Notes |
|---|---|---|
| For patients weighing 50 kg or more | Give Ferintus 500 mg in two doses separated by at least 7 days | Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course |
| For patients weighing less than 50 kg | Give Ferintus 500 mg in two doses separated by at least 7 days | Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course. The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency anemia reoccurs. Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes. When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded. Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site |
Dosage of Ferintus 500 mg
For patients weighing 50 kg or more
Dosage:Give Ferintus 500 mg in two doses separated by at least 7 days
Notes:Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course
For patients weighing less than 50 kg
Dosage:Give Ferintus 500 mg in two doses separated by at least 7 days
Notes:Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course. The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency anemia reoccurs. Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes. When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded. Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site
| Condition | Dosage | Notes |
|---|---|---|
| For patients weighing 50 kg or more | Give Ferintus 500 mg in two doses separated by at least 7 days | Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course |
| For patients weighing less than 50 kg | Give Ferintus 500 mg in two doses separated by at least 7 days | Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course. The dosage of Ferintus 500 mg is expressed in mg of elemental iron. Each mL of Ferintus 500 mg contains 50 mg of elemental iron. Ferintus 500 mg treatment may be repeated if iron deficiency anemia reoccurs. Administer Ferintus 500 mg intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes. When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferintus 500 mg solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferintus 500 mg is intended for single use only. Any unused drug remaining after injection must be discarded. Avoid extravasation of Ferintus 500 mg since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferintus 500 mg administration at that site |
Interaction of Ferintus 500 mg
There are no known drug interactions and none well documented.
Contraindications
Hypersensitivity to any of its components.
Side Effects of Ferintus 500 mg
Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions
Pregnancy & Lactation
Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Precautions & Warnings
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.Hypertension: Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.
Storage Conditions
Do not store above 30°C. Do not freeze.
Drug Classes
Parenteral Iron Preparations
Mode Of Action
Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.
Pregnancy
Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Frequently Asked Questions
What is Ferintus 500 mg used for?
Ferric Carboxymaltose is indicated for the treatment of iron deficiency anemia in adult patients- Who have intolerance to oral iron or have had unsatisfactory response to oral iron Who have non-dialysis dependent chronic kidney disease.
What is the dosage of Ferintus 500 mg?
For patients weighing 50 kg or more: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg o…
What are the side effects of Ferintus 500 mg?
Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions
Who should not take Ferintus 500 mg?
Hypersensitivity to any of its components.
What precautions should be taken with Ferintus 500 mg?
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and a…
Is Ferintus 500 mg safe during pregnancy and breastfeeding?
Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.